Also trades as: SABS (NASDAQ) · $vol 2M
SABSW NASDAQ
SAB Biotherapeutics, Inc.
1W: +20.1%
1M: -2.5%
3M: -50.6%
YTD: -36.5%
1Y: -33.2%
3Y: -86.9%
$0.02
+0.00 (+1.24%)
Weekly Expected Move ±112.6%
$-0
$-0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.2M
52W Range0.0163-0.0477
Volume2,000
Avg Volume24,327
Beta0.12
Dividend—
Analyst Ratings
Company Info
CEOSamuel J. Reich
Employees63
SectorHealthcare
IndustryBiotechnology
IPO Date2021-10-25
Websitesabbiotherapeutics.com
2100 East 54th Street North
Sioux Falls, SD 33140
US
Sioux Falls, SD 33140
US
605-679-6980
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
Latest News
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
Emergent BioSolutions signs multi-year manufacturing deal with SAB Biotherapeutics worth about $50M
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of “Moderate Buy” from Analysts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kropotova Alexandra | F-InKind | 988 | — | 2026-03-24 |
| Jain Rita | 0 | — | 2026-01-05 | |
| ZACCARDELLI DAVID | 0 | — | 2026-01-05 | |
| Kropotova Alexandra | F-InKind | 988 | — | 2025-12-11 |
| Moin Andrew | M-Exempt | 17,400 | $1.75 | 2025-09-29 |